Cargando…

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients

Detalles Bibliográficos
Autores principales:	Ramanan, Vijay K., Day, Gregory S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304213/ https://www.ncbi.nlm.nih.gov/pubmed/37381015 http://dx.doi.org/10.1186/s13024-023-00637-0

Ejemplares similares

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

The tip of the iceberg? The underestimated potential of non-canonical beta-amyloids for Alzheimer’s disease
por: Busch, Lukas, et al.
Publicado: (2023)

A crate of Pandora: do amyloids from bacteria promote Alzheimer’s disease?
por: Nguyen, Vu Thu Thuy, et al.
Publicado: (2020)

Putative roles of cathepsin B in Alzheimer's disease pathology: the good, the bad, and the ugly in one?
por: Bernstein, Hans-Gert, et al.
Publicado: (2018)

The Amyloid Cascade Hypothesis 2.0 for Alzheimer’s Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy
por: Volloch, Vladimir, et al.
Publicado: (2023)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Consequences of redefining Alzheimer's disease in terms of amyloid burden without regard to cognitive decline
por: Robinson, Stephen R., et al.
Publicado: (2018)

Misfolded amyloid-β strains and their potential roles in the clinical and pathological variability of Alzheimer’s disease
por: Kelley, Sara, et al.
Publicado: (2022)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

Anti-amyloid therapies work for Alzheimer’s disease
por: Hardy, John
Publicado: (2023)

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
por: Gandy, Sam
Publicado: (2023)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer’s disease
por: Wang, Liang, et al.
Publicado: (2022)

Beta‐amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease
por: Pannuzzo, Martina
Publicado: (2021)

Finally, Some Neurophysiologic Good News—Favorable Prognosis in Coma
por: Husain, Aatif M.
Publicado: (2019)

Finally good NEWS: Something simple is working in COVID-19!
por: Subbe, Christian, et al.
Publicado: (2021)

Cyclic adenosine monophosphate-elevating agents inhibit amyloid-beta internalization and neurotoxicity: their action in Alzheimer’s disease prevention
por: Gopalakrishna, Rayudu, et al.
Publicado: (2023)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

Might Fibroblasts from Patients with Alzheimer’s Disease Reflect the Brain Pathology? A Focus on the Increased Phosphorylation of Amyloid Precursor Protein Tyr(682) Residue
por: Iannuzzi, Filomena, et al.
Publicado: (2021)

In the name of the greater good?
por: Kirkwood, K
Publicado: (2010)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

Artemisinin Combination Therapy: A Good Antimalarial, but Is the Dose Right?
por: Garner, Paul
Publicado: (2013)

Are we ready to use anti-amyloid therapy in Alzheimer's disease?
por: Brucki, Sonia Maria Dozzi, et al.
Publicado: (2022)

LL-37 and CsgC exemplify the crosstalk between anti-amyloid, antimicrobial, and anti-biofilm protein activities
por: Santos, Jaime, et al.
Publicado: (2022)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
por: Lu, Xinjie, et al.
Publicado: (2008)

Phosphorylation of amyloid beta (Aβ) peptides – A trigger for formation of toxic aggregates in Alzheimer's disease
por: Kumar, Sathish, et al.
Publicado: (2011)

Hyperbaric oxygen therapy as a new treatment approach for Alzheimer’s disease
por: Shapira, Ronit, et al.
Publicado: (2018)

The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
por: Walgrave, Hannah, et al.
Publicado: (2021)

Biomarker-guided drug therapy: personalized medicine for treating Alzheimer’s disease
por: Syal, Charvi, et al.
Publicado: (2021)

Direct oral anticoagulants: a new therapy against Alzheimer’s disease?
por: Grossmann, Klaus
Publicado: (2021)

How useful are biomarkers for the diagnosis of Alzheimer’s disease and especially for its therapy?
por: Valenza, Marta, et al.
Publicado: (2022)

Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
por: Castello, Michael A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2i5rsi5apq6iccfif6gvmna78p